# BiGvCL: bipartite graph-based cross-domain contrastive learning model for the predicting drug-gene interactions

**Authors:** Shida He, Zixu Wang, Jing Li, Quan Zou, Feng Zhang

PMC · DOI: 10.1093/bib/bbaf710 · Briefings in Bioinformatics · 2026-01-28

## TL;DR

BiGvCL is a new model that predicts drug-gene interactions using network structure, without needing detailed chemical or genetic features.

## Contribution

BiGvCL introduces a novel topology-based framework using graph attention and contrastive learning to predict drug-gene interactions.

## Key findings

- BiGvCL achieves competitive performance on DrugBank and DGIdb datasets.
- The model shows adaptability to heterogeneous biomedical networks through cross-domain evaluations.
- Contrastive and gated mechanisms significantly contribute to model performance.

## Abstract

Drug-gene interactions (DGIs) influence the toxicity or ineffectiveness of the drug therapy and play an important role in elucidating drug mechanisms, predicting potential adverse effects, and facilitating precision medicine. Existing computational methods typically rely on chemical or genetic sequence features of drugs and genes, limiting their effectiveness for novel entities lacking explicit annotations. To address this, we propose BiGvCL, a framework that predicts DGIs exclusively based on network topology, requiring no explicit feature information for drugs or genes. BiGvCL introduces a lightweight graph attention mechanism (GATLite) to efficiently aggregate local neighborhood information. Additionally, we develop a gated graph convolutional network (GatedGCN) to explicitly learn high-order interactions between drugs and genes, further integrating contrastive learning to enhance the model’s generalizability. Comprehensive experiments on DrugBank and DGIdb datasets show that BiGvCL achieves competitive performance across all metrics compared with representative baselines. Cross-domain evaluations on OGB datasets further confirm its adaptability to heterogeneous biomedical networks. Ablation and hyperparameter analyses highlight the key contributions of contrastive and gated mechanisms, while case studies and molecular docking provide supporting evidence for the biological relevance of predictions. Collectively, while BiGvCL is constrained by its reliance on network topology and transductive learning paradigm, it demonstrates the potential of topology-based approaches for discovering novel drug-gene interactions, which may inform drug repurposing and precision medicine efforts.

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, GABARAP (GABA type A receptor-associated protein) [NCBI Gene 11337] {aka ATG8A, GABARAP-a, MM46}, DOCK2 (dedicator of cytokinesis 2) [NCBI Gene 1794] {aka IMD40}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}
- **Diseases:** inflammatory (MESH:D007249), DGIs (MESH:D000014), toxicity (MESH:D064420), colon, gastric, bladder, prostate, and lung cancers (MESH:D008175), cancers (MESH:D009369), infectious diseases (MESH:D003141), DGI (MESH:D003811)
- **Chemicals:** Quetiapine (MESH:D000069348), ritonavir (MESH:D019438), Lamotrigine (MESH:D000077213), PAZOPANIB (MESH:C516667), Bretazenil (MESH:C054626), metyrapone (MESH:D008797), Flumazenil (MESH:D005442), 1W0E (-), Aripiprazole (MESH:D000068180), Escitalopram (MESH:D000089983), Rapastinel (MESH:C507283), Hesperadin (MESH:C474723), REGN421 (MESH:C000600154)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12848949/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12848949/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12848949/full.md

---
Source: https://tomesphere.com/paper/PMC12848949